268 related articles for article (PubMed ID: 24692731)
1. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.
Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y
Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
van den Broek MA; Vreuls CP; Winstanley A; Jansen RL; van Bijnen AA; Dello SA; Bemelmans MH; Dejong CH; Driessen A; Olde Damink SW
Ann Surg Oncol; 2013 May; 20(5):1462-9. PubMed ID: 23463086
[TBL] [Abstract][Full Text] [Related]
3. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
[TBL] [Abstract][Full Text] [Related]
4. von Willebrand Factor-Rich Platelet Thrombi in the Liver Cause Sinusoidal Obstruction Syndrome following Oxaliplatin-Based Chemotherapy.
Nishigori N; Matsumoto M; Koyama F; Hayakawa M; Hatakeyayama K; Ko S; Fujimura Y; Nakajima Y
PLoS One; 2015; 10(11):e0143136. PubMed ID: 26580395
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.
Overman MJ; Maru DM; Charnsangavej C; Loyer EM; Wang H; Pathak P; Eng C; Hoff PM; Vauthey JN; Wolff RA; Kopetz S
J Clin Oncol; 2010 May; 28(15):2549-55. PubMed ID: 20406923
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases.
Ribero D; Wang H; Donadon M; Zorzi D; Thomas MB; Eng C; Chang DZ; Curley SA; Abdalla EK; Ellis LM; Vauthey JN
Cancer; 2007 Dec; 110(12):2761-7. PubMed ID: 17960603
[TBL] [Abstract][Full Text] [Related]
8. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
[TBL] [Abstract][Full Text] [Related]
9. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis.
Rubbia-Brandt L; Lauwers GY; Wang H; Majno PE; Tanabe K; Zhu AX; Brezault C; Soubrane O; Abdalla EK; Vauthey JN; Mentha G; Terris B
Histopathology; 2010 Mar; 56(4):430-9. PubMed ID: 20459550
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
Stevenson HL; Prats MM; Sasatomi E
BMC Cancer; 2017 Jan; 17(1):35. PubMed ID: 28061766
[TBL] [Abstract][Full Text] [Related]
11. Sinusoidal dilation increases the risk of complications in hepatectomy for CRCLM - Protective effect of bevacizumab and diabetes mellitus, serum gamma-glutamyltranspeptidase as predictive factor.
Martins J; Alexandrino H; Oliveira R; Cipriano MA; Falcão D; Ferreira L; Martins R; Serôdio M; Martins M; Tralhão JG; Prado e Castro L; Castro E Sousa F
Eur J Surg Oncol; 2016 May; 42(5):713-21. PubMed ID: 26972374
[TBL] [Abstract][Full Text] [Related]
12. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases.
Morris-Stiff G; White AD; Gomez D; Cameron IC; Farid S; Toogood GJ; Lodge JP; Prasad KR
Eur J Surg Oncol; 2014 Aug; 40(8):1016-20. PubMed ID: 24370284
[TBL] [Abstract][Full Text] [Related]
13. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab.
Hubert C; Sempoux C; Humblet Y; van den Eynde M; Zech F; Leclercq I; Gigot JF
HPB (Oxford); 2013 Nov; 15(11):858-64. PubMed ID: 23458554
[TBL] [Abstract][Full Text] [Related]
14. Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX.
Kim MJ; Han SW; Lee DW; Cha Y; Lee KH; Kim TY; Oh DY; Kim SH; Im SA; Bang YJ; Kim TY
Cancer Res Treat; 2016 Jul; 48(3):990-7. PubMed ID: 26790967
[TBL] [Abstract][Full Text] [Related]
15. Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography.
Osawa G; Yoshimatsu K; Yokomizo H; Okayama S; Sagawa M; Naritaka Y
Cancer Chemother Pharmacol; 2013 Jul; 72(1):209-15. PubMed ID: 23670642
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience.
Cvetanovic A; Vrbic S; Filipovic S; Pejcic I; Milenkovic D; Milenkovic N; Zivkovic N
J BUON; 2013; 18(3):641-6. PubMed ID: 24065477
[TBL] [Abstract][Full Text] [Related]
17. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
Duwe G; Knitter S; Pesthy S; Beierle AS; Bahra M; Schmelzle M; Schmuck RB; Lohneis P; Raschzok N; Öllinger R; Sinn M; Struecker B; Sauer IM; Pratschke J; Andreou A
Eur J Surg Oncol; 2017 Sep; 43(9):1668-1681. PubMed ID: 28599872
[TBL] [Abstract][Full Text] [Related]
18. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival.
Viganò L; Capussotti L; De Rosa G; De Saussure WO; Mentha G; Rubbia-Brandt L
Ann Surg; 2013 Nov; 258(5):731-40; discussion 741-2. PubMed ID: 24045448
[TBL] [Abstract][Full Text] [Related]
19. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases.
van der Pool AE; Marsman HA; Verheij J; Ten Kate FJ; Eggermont AM; Ijzermans JN; Verhoef C
J Surg Oncol; 2012 Dec; 106(7):892-7. PubMed ID: 22552819
[TBL] [Abstract][Full Text] [Related]
20. Changes in Noninvasive Liver Fibrosis Indices and Spleen Size During Chemotherapy: Potential Markers for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome.
Park S; Kim HY; Kim H; Park JH; Kim JH; Kim KH; Kim W; Choi IS; Jung YJ; Kim JS
Medicine (Baltimore); 2016 Jan; 95(2):e2454. PubMed ID: 26765438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
